• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过 ZMYND8 使 IDH 突变型脑胶质瘤增敏——改善预后的途径。

Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.

机构信息

Department of Radiation Oncology, Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.

Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

出版信息

Clin Cancer Res. 2023 May 1;29(9):1648-1650. doi: 10.1158/1078-0432.CCR-23-0018.

DOI:10.1158/1078-0432.CCR-23-0018
PMID:36826993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10159893/
Abstract

Isocitrate dehydrogenase 1-mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radioresistance for IDH1m gliomas, and pharmacologic targeting of this pathway may heighten radiotherapy-induced tumor response, providing a prospect of improved clinical outcomes. See related article by Carney et al., p. 1763.

摘要

异柠檬酸脱氢酶 1 突变型 (IDH1m) 胶质瘤是一种难以治疗的肿瘤，放疗仍然是其标准治疗方法。最近的一项研究确定 ZMYND8 是 IDH1m 胶质瘤放射抵抗的关键介质，该途径的药物靶向可能会增强放疗诱导的肿瘤反应，从而提供改善临床结果的前景。见 Carney 等人的相关文章，第 1763 页。

相似文献

1
Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.通过 ZMYND8 使 IDH 突变型脑胶质瘤增敏——改善预后的途径。
Clin Cancer Res. 2023 May 1;29(9):1648-1650. doi: 10.1158/1078-0432.CCR-23-0018.
2
Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance.锌指 MYND 型包含 8 （ZMYND8）在突变型异柠檬酸脱氢酶 1 （IDH1）胶质瘤中受表观遗传调控，以促进放射抵抗。
Clin Cancer Res. 2023 May 1;29(9):1763-1782. doi: 10.1158/1078-0432.CCR-22-1896.
3
Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.异柠檬酸脱氢酶 1 突变型人脑胶质瘤依赖于乳酸和谷氨酸来缓解代谢应激。
FASEB J. 2019 Jan;33(1):557-571. doi: 10.1096/fj.201800907RR. Epub 2018 Jul 12.
4
Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.异柠檬酸脱氢酶突变与成人胶质瘤中 OLIG2 的不同表达和 DNA 甲基化模式相关。
J Neuropathol Exp Neurol. 2022 Aug 16;81(9):707-716. doi: 10.1093/jnen/nlac059.
5
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.IDH1/2 突变通过扰乱神经胶质瘤中的细胞代谢来靶向癌症的一个关键标志。
Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21.
6
Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.异柠檬酸脱氢酶突变型脑胶质瘤免疫微环境及免疫治疗的研究进展
Front Immunol. 2022 Jun 13;13:914618. doi: 10.3389/fimmu.2022.914618. eCollection 2022.
7
Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.脑胶质瘤异柠檬酸脱氢酶突变的免疫治疗潜力进展。
Neurosci Bull. 2022 Sep;38(9):1069-1084. doi: 10.1007/s12264-022-00866-1. Epub 2022 Jun 7.
8
[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].[中国胶质瘤患者异柠檬酸脱氢酶基因突变情况]
Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):292-8. doi: 10.3760/cma.j.issn.0529-5807.2013.05.002.
9
2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas.异柠檬酸脱氢酶（IDH）突变导致的2-羟基戊二酸积累与恶性胶质瘤的形成有关。
Expert Rev Neurother. 2010 Apr;10(4):487-9. doi: 10.1586/ern.10.19.
10
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.异柠檬酸脱氢酶突变状态对体内低氧生物标志物表达的影响：33 例胶质瘤患者临床、核医学影像和免疫组织化学研究的新见解。
J Neurooncol. 2011 Dec;105(3):591-600. doi: 10.1007/s11060-011-0625-2. Epub 2011 Jun 5.

本文引用的文献

1
Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance.锌指 MYND 型包含 8 （ZMYND8）在突变型异柠檬酸脱氢酶 1 （IDH1）胶质瘤中受表观遗传调控，以促进放射抵抗。
Clin Cancer Res. 2023 May 1;29(9):1763-1782. doi: 10.1158/1078-0432.CCR-22-1896.
2
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.CODEL：新诊断的 1p/19q 共缺失型少突胶质细胞瘤接受放疗、放疗 +TMZ 或 TMZ 治疗的 III 期研究。基于初始研究设计的分析。
Neuro Oncol. 2021 Mar 25;23(3):457-467. doi: 10.1093/neuonc/noaa168.
3
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
IDH1-R132H 通过表观遗传地上调 DNA 损伤反应在神经胶质瘤中作为肿瘤抑制因子发挥作用。
Sci Transl Med. 2019 Feb 13;11(479). doi: 10.1126/scitranslmed.aaq1427.
4
Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.靶向 DNA 双链断裂修复途径以提高放射治疗反应。
Genes (Basel). 2019 Jan 4;10(1):25. doi: 10.3390/genes10010025.
5
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.NRG 肿瘤学 RTOG 9006：一项 III 期随机临床试验，比较超分割放疗 (RT) 和 BCNU 与标准 RT 和 BCNU 治疗恶性胶质瘤患者的效果。
J Neurooncol. 2018 Mar;137(1):39-47. doi: 10.1007/s11060-017-2558-x. Epub 2018 Feb 5.
6
ZMYND8 Co-localizes with NuRD on Target Genes and Regulates Poly(ADP-Ribose)-Dependent Recruitment of GATAD2A/NuRD to Sites of DNA Damage.ZMYND8与NuRD在靶基因上共定位，并调节GATAD2A/NuRD依赖于聚（ADP-核糖）的DNA损伤位点募集。
Cell Rep. 2016 Oct 11;17(3):783-798. doi: 10.1016/j.celrep.2016.09.037.
7
Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?治疗指征：在低级别胶质瘤的管理中，单纯观察或化疗是否是一种合理的方法？
Semin Radiat Oncol. 2015 Jul;25(3):203-9. doi: 10.1016/j.semradonc.2015.02.008. Epub 2015 Feb 23.
8
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.替莫唑胺、洛莫司汀和长春新碱治疗少突胶质细胞瘤获益与 IDH 突变相关。
J Clin Oncol. 2014 Mar 10;32(8):783-90. doi: 10.1200/JCO.2013.49.3726. Epub 2014 Feb 10.
9
DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.DNA 双链断裂修复作为细胞放射杀伤敏感性和放射治疗靶区的决定因素。
Front Oncol. 2013 May 10;3:113. doi: 10.3389/fonc.2013.00113. eCollection 2013.
10
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.同步放化疗联合辅助替莫唑胺与单纯放疗对胶质母细胞瘤生存影响的随机III期研究：EORTC-NCIC试验的5年分析
Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.